Better CLIA Compliance: Reviewing Top Deficiencies from Accreditors and Looking to Future CLIA Reform
Published August 2023 | Introductory Price $99
Operating the clinical laboratory within a culture of up-to-date CLIA compliance means that all clinical laboratory directors must quickly adapt to old, new, and evolving regulatory requirements. Missteps in the lab whether intentional or not can impose serious consequences: principal sanctions, civil monetary penalties, limitation or revocation of licensure, a cease and desist of lab testing order, and a two-year ban of the lab director.
This 36-page special report—brought to you by The Dark Report and The Dark Intelligence Group—supports those aiming for excellence in compliance-focused lab operations. Better CLIA Compliance: Reviewing Top Deficiencies from Accreditors and Looking to Future CLIA Reform is designed to give lab directors and compliance officers knowledge and confidence to better oversee their labs’ CLIA compliance efforts.
Developed from candid conversations with all the key players in clinical laboratory accreditation, certification, and regulatory interpretation, each chapter is designed to build on and deepen the lab leader’s knowledge of essential components of CLIA compliance. Easily add this valuable workbook to the training and education component of your lab’s regulatory compliance program.
State of the Genetic Testing Marketplace: Getting Paid for All Your Lab’s Genetic Test Claims—What’s Changing, What’s Not, and What’s Working Best,
Published August 4, 2021 | $195
Genetic testing is the fastest-growing sector of clinical laboratory medicine. Over the past decade, the intersection of policymakers, entrepreneurs, investors, and healthcare leaders has advanced innovative methods of predictive, diagnostic, and research-related forms of advanced molecular and genetic testing.
However, genetic testing laboratories face an ongoing dynamic business landscape where their tests will be questioned more often than not—at the same time as record-level payer spending occurs in some testing categories. Commercial payers, in particular, dictate strict coverage criteria for how they accept and pay for genetic test claims, which can cost thousands of dollars per test.
The good news? The business of genetic and molecular testing is robust for labs—even with these revenue cycle vulnerabilities. Every clinical laboratory and genetic test company can significantly increase net collected revenue and reduce denials, but only if their team understands how to meet requirements for clean claims.
This special report will help you and your lab team better align genetic test claims in ways that reduce denials, thus bringing in more revenue. Of equal importance, it provides best practices to help your lab work with referring physicians to obtain prior authorization for a larger proportion of genetic test requests AND have the documents necessary to support prior authorization and any payer audits that could come later. LEARN MORE OR ORDER NOW
Getting Paid for COVID-19 Test Claims: What Every Clinical Lab Needs to Know to Maximize Collected Dollars
Published March 26, 2021 | 118 pages | $599
As many labs have discovered, getting reimbursed for COVID-19 tests is not a given. Several sources of risk—inadequate posting of prices, improper coding, noncompliance with state & federal laws, and improper documentation—result in labs not being paid for COVID-19 testing or, more likely, getting paid and later facing audits that result in the recoupment of some payments.
This 118-page report covers all the key risk areas and provides guidance on how clinical laboratories can maximize dollars collected for COVID-19 testing.
LEARN MORE OR ORDER NOW
UPDATED & REVISED! COVID-19 Employee Testing and Screening Programs: Essential Guidance on Legal, Risk Management, Regulatory, and Compliance Issues for All Employers
Published January, 2021 | $599
With greater understanding of COVID-19, many organizations—even those that would not normally engage in workplace testing—are assessing how they will approach health and safety in their workforce, customer, and student communities. But implementing an employee COVID-19 screening and testing program is unfamiliar territory for most employers.
This new special report serves as the essential reference for those either embarking on a COVID-19 employee testing and screening program or reviewing a program already in place. LEARN MORE OR ORDER NOW
What Hospital and Health Network Labs Must Know to Comply with PAMA Private Payer Price Reporting
Published June, 2019 | $749
This comprehensive workshop is designed to help hospital CEOs, CFOs, their laboratory administrators, and others tasked with data reporting and other requirements of PAMA to fulﬁll this federal law, with the data reported used to calculate an updated Clinical Laboratory Fee Schedule expected to go into effect Jan. 1, 2021.
“What Hospital and Health Network Clinical Laboratories Must Know to Comply with PAMA Private Payer Price Reporting” is based on federal guidance, enhanced by the expertise of health law practice attorneys, health system leaders who are already reporting data, and other experts. This series of 8 videos comes with a comprehensive companion PDF handbook that supplements the videos, and helps weave together the maze of federal guidance into a wealth of easily accessible resources.
This program package is an ideal educational and training tool for each team member tasked with the PAMA data reporting project, as well as the hospital, health system, and medical laboratory leader who must certify their organization’s data to CMS in a timely manner. LEARN MORE OR ORDER NOW